Pliant Therapeutics Inc Ordinary Shares PLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
-
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
-
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
-
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
-
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
Trading Information
- Previous Close Price
- $11.17
- Day Range
- $11.30–11.62
- 52-Week Range
- $10.29–19.62
- Bid/Ask
- $11.31 / $13.35
- Market Cap
- $687.66 Mil
- Volume/Avg
- 216,050 / 493,789
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 166
- Website
- https://www.pliantrx.com
Comparables
Valuation
|
Metric
|
PLRX
|
TERN
|
TVTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.74 | 2.75 | 70.72 |
Price/Sales | — | — | 6.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
PLRX
TERN
TVTX
Financial Strength
|
Metric
|
PLRX
|
TERN
|
TVTX
|
|---|---|---|---|
Quick Ratio | 14.21 | 20.57 | 2.89 |
Current Ratio | 14.47 | 21.02 | 3.04 |
Interest Coverage | −106.49 | — | −35.20 |
Quick Ratio
PLRX
TERN
TVTX
Profitability
|
Metric
|
PLRX
|
TERN
|
TVTX
|
|---|---|---|---|
Return on Assets (Normalized) | −27.65% | −28.87% | −9.03% |
Return on Equity (Normalized) | −31.11% | −30.36% | −47.00% |
Return on Invested Capital (Normalized) | −33.69% | −34.37% | −13.68% |
Return on Assets
PLRX
TERN
TVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gtxbwzhjn | Smqts | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Sspyfyffs | Hgzqy | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fhgpbzpzl | Tstrx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lvjkkwrv | Phdtvg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gcppksyqr | Kpmw | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Njfdmcj | Vftb | $28.1 Bil | |||
| Moderna Inc
MRNA
| Pjhznmn | Hkfdz | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Gjbpvvww | Vhpd | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lsyphspf | Yskrmk | $13.4 Bil | |||
| Incyte Corp
INCY
| Hffbyynz | Qdccjs | $12.7 Bil |
United States